NICE rejects Alnylam and Akcea’s amyloidosis drugs
Lojuxta will be available to patients this year
Strimvelis is most expensive drug cleared by NICE
A UK biotech start-up has gained a sought after ‘promising innovative medicine’ (PIM) designation for its ultra-rare disease gene therapy.
Managed access scheme will control costs to NHS.
Sucampo gains rights to a drug for rare genetic disorder.
Former AZ chief David Brennan expected to take over as chairman in May.